CRNX Crinetics Pharmaceuticals, Inc. - Common Stock

NASDAQ · Pharmaceuticals · SEC EDGAR पर देखें ↗
$84.71
मूल्य · अग 20, 2026
मौलिकता इस प्रकार है अग 3, 2026
52W रेंज
$29–$85
100% of range
विश्लेषक रेटिंग
HOLD
21 analysts
मूल्य लक्ष्य
$86
+1% upside
P/E (TTM)
-17.1
ROE
-43.0%
शुद्ध लाभ मार्जिन
-6046.2%

Crinetics Pharmaceuticals, Inc. - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन

Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.

और पढ़ें

Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.

In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion.

History

Struthers, Zhu, Kusnetzow, and Betz founded Crinetics in 2008 after previously working together on a small molecule drug for the treatment of endometriosis at Neurocrine Biosciences.

Crinetics expanded into a larger laboratory in 2010. After receiving NIH grant funding, Crinetics moved into its second laboratory.

In 2011, Crinetics Pharmaceuticals competed for the Michelson Prize, a competition sponsored by the Found Animals Foundation to develop a low-cost, non-surgical method for sterilizing dogs and cats, which would later lead to the licensing of a molecule for the treatment of acromegaly in large breed dogs.

Crinetics first synthesized its lead drug candidate to treat acromegaly. The drug was named paltusotine, in 2016. Crinetics Pharmaceuticals went public with an IPO in 2018. It conducted Phase II trials for paltusotine from 2019 to 2020. It conducted Phase III trials for paltusotine from 2021 to 2024. After the drug succeeded in a second Phase III study, the FDA accepted the company's new drug application for paltusotine and the company announced it was planning for a 2025 launch for the drug. The FDA set a Prescription Drug User Fee Act for the drug on September 25, 2025.

In 2021, Crinetics, together with 5AM Ventures and Frazier Healthcare Partners, formed an independently operated new company, Radionetics Oncology, aimed to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the treatment of a broad range of oncology indications.

Crinetics partnered with the veterinary medicine company Loyal to develop a pill to extend the lifespans of large dogs in 2023.

In 2024, Scott Struthers received the Ernst & Young Entrepreneur of the Year Award for his work with Crinetics. In 2024, Crinetics was reported to have patent activity in rare diseases, health technology, and addiction therapies.

In 2024, Radionetics formed a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million upfront cash payment. As part of the strategic agreement, Lilly obtained the exclusive right to acquire Radionetics upon conclusion of an exercise period for $1 billion.

Crinetics also established its first office outside the United States in Zug, Switzerland in 2024.

In 2025, Crinetics Pharmaceuticals plans to file an Investigational New Drug for an oral thyroid stimulating hormone receptor antagonist and its nonpeptide drug conjugate (CRN09682). A total of four development candidates are currently in IND-enabling studies, including a PTH antagonist (Hyperparathyrodism), non-peptide drug conjugate (NETs and SST2-expressing solid tumors), TSH antagonist (Graves’ disease & TED) and SST3 agonist (ADPKD).

In July 2026, Vertex Pharmaceuticals agreed to acquire Crinetics for $10 billion.

Treatments

Crinetics’ pipeline focuses on synthesizing novel molecules for rare endocrine diseases. It is most known for developing paltusotine, a drug designed to treat the hormonal disorder acromegaly. Paltusotine works by helping moderate elevated IGF-1 levels, which is the main symptom of acromegaly. Paltusotine has also been tested as a treatment for carcinoid syndrome.

Crinetics has also developed oral treatments for neuroendocrine tumors, hyperinsulism, and Cushing's disease. The company's drug for treating Cushing's disease, Atumeltnant (also known as CRN049894), works by reducing levels of ACTH.

The company's pipeline also includes an oral parathyroid hormone inhibitor program for hyperparathyroidism and treatments for thyroid eye disease, Graves' disease, and obesity. Additionally, Crinetics nonpeptide drug conjugates (NDCs) include CRN09682, which is a somatostatin receptor 2 (SST2) targeted drug. NDCs are a new technology developed in-house by Crinetics.

== References ==

स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗

Wikidata ↗

CRNX स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा

मूल्य
$84.70
मार्केट कैप
$8.10B
P/E (TTM)
-17.1
EPS (TTM)
$-4.95
राजस्व (TTM)
$8M
लाभांश प्रतिफल
—
ROE
-43.0%
D/E ऋण/इक्विटी
—
52W रेंज
$29 – $85

CRNX स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें

10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान

राजस्व और शुद्ध आय $8M
10-point trend, +1206.6%
2016-12-31 → 2025-12-31
EPS $-4.95
6-point trend, -104.5%
2020-12-31 → 2025-12-31
फ्री कैश फ्लो $-384M
8-point trend, -1770.0%
2018-12-31 → 2025-12-31
मार्जिन -6046.2%

मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?

मेट्रिक
5Y रुझान
CRNX
सहकर्मी माध्यिका
P/E (TTM)
5-point trend, +7.3%
-17.1
47.9
P/S (TTM)
5-point trend, -53.9%
1051.9
16.2
P/B
5-point trend, +10.1%
8.2
9.3
Price / FCF (मूल्य / FCF)
5-point trend, +23.7%
-21.1
—

लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC

मेट्रिक
5Y रुझान
CRNX
सहकर्मी माध्यिका
Operating Margin (परिचालन मार्जिन)
5-point trend, +32.8%
-6714.8%
—
Net Profit Margin (शुद्ध लाभ मार्जिन)
5-point trend, +39.4%
-6046.2%
5.1%
ROA
5-point trend, +9.8%
-36.3%
0.81%
ROE
5-point trend, -5.0%
-43.0%
-15.3%
ROIC
5-point trend, -60.6%
-52.1%
—

वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती

मेट्रिक
5Y रुझान
CRNX
सहकर्मी माध्यिका
Current Ratio (वर्तमान अनुपात)
5-point trend, -42.8%
12.3
2.7
Quick Ratio (त्वरित अनुपात)
5-point trend, -42.1%
12.1
—

विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR

मेट्रिक
5Y रुझान
CRNX
सहकर्मी माध्यिका
Revenue YoY (राजस्व YoY)
5-point trend, +613.9%
640.7%
—
Revenue CAGR 3Y (राजस्व CAGR 3Y)
5-point trend, +613.9%
17.6%
—
Revenue CAGR 5Y (राजस्व CAGR 5Y)
5-point trend, +613.9%
155.3%
—

प्रति शेयर मेट्रिक्स EPS, प्रति शेयर बुक वैल्यू, प्रति शेयर नकदी प्रवाह, प्रति शेयर लाभांश

मेट्रिक
5Y रुझान
CRNX
सहकर्मी माध्यिका
EPS (Diluted) (EPS (तनुभूत))
5-point trend, -76.8%
$-4.95
—

पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर

मेट्रिक
5Y रुझान
CRNX
सहकर्मी माध्यिका

CRNX विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड

होल्ड 21 विश्लेषक
  • मजबूत खरीद 3 14.3%
  • खरीदें 4 19.0%
  • होल्ड 14 66.7%
  • बेचें 0 0.0%
  • मजबूत बिक्री 0 0.0%

12-महीने का मूल्य लक्ष्य

10 विश्लेषक · 2026-08-20
मध्यिका लक्ष्य $85.00 +0.3%
माध्य लक्ष्य $85.50 +0.9%

Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि

औसत आश्चर्य
-0.01%
Period EPS Actual EPS अनुमान आश्चर्य
30 जून 2026 $-1.14 $-1.23 0.09%
31 मार्च 2026 $-1.23 $-1.26 0.03%
31 दिसमबर 2025 $-1.29 $-1.39 0.10%
30 सितमबर 2025 $-1.38 $-1.28 -0.10%
30 जून 2025 $-1.23 $-1.12 -0.11%
31 मार्च 2025 $-1.04 $-0.96 -0.08%

सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी

टिकर मार्केट कैप P/E राजस्व YoY शुद्ध मार्जिन ROE सकल मार्जिन
CRNX $4.45B -9.4 640.7% -6046.2% -43.0% —
CORT $3.69B 42.4 12.8% 13.1% 15.5% —
ELAN $11.25B -48.1 6.2% -4.9% -3.5% 55.0%
AXSM $9.29B -49.6 65.5% -28.7% -227.0% —
LQDA $3.01B -43.1 1031.2% -43.5% -230.0% —
BLTE — — — — — —
DFTX $1.32B -6.5 212.0% — -71.0% —
AMRX — 57.3 8.1% 2.4% -80.0% 36.9%
LGND $3.74B 30.8 60.4% 46.4% 13.5% —
LLY — 46.8 44.7% 31.7% 101.2% —

पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह

आय विवरण 17
CRNX के लिए वार्षिक आय विवरण डेटा
मेट्रिक रुझान 202520242023202220212020201920182017
Revenue 9-point trend, +276.3% $8M $1M $4M $5M $1M $71.0K $1M $2M $2M
Cost of Revenue 3-point trend, +1076000.00 $1M $0 $0 · · · · · ·
R&D Expense 9-point trend, +3496.4% $332M $240M $169M $130M $84M $57M $42M $24M $9M
SG&A Expense 9-point trend, +9767.5% $191M $100M $58M $42M $25M $18M $14M $7M $2M
Operating Expenses 9-point trend, +4594.5% $524M $340M $227M $173M $109M $75M $55M $31M $11M
Operating Income 9-point trend, -5562.0% $-517M $-339M $-223M $-168M $-108M $-75M $-54M $-29M $-9M
Interest Expense · · · · · · · · $8.0K
Interest Income 9-point trend, +199857.7% $52M $41M $13M $4M $157.0K $991.0K $3M $2M $26.0K
Other Non-op 9-point trend, -1090.0% $-357.0K $-519.0K $-159.0K $5M $61.0K $1M $3M $2M $-30.0K
Pretax Income 9-point trend, -4979.6% $-465M $-298M $-209M $-164M $-108M $-74M $-50M $-27M $-9M
Income Tax 9-point trend, +180000.00 $180.0K $0 $0 $0 $0 $0 $0 $0 $0
Net Income 9-point trend, -4981.5% $-465M $-298M $-215M $-164M $-108M $-74M $-50M $-27M $-9M
EPS (Basic) 6-point trend, -104.5% $-4.95 $-3.69 $-3.69 $-3.15 $-2.80 $-2.42 · · ·
EPS (Diluted) 6-point trend, -104.5% $-4.95 $-3.69 $-3.69 $-3.15 $-2.80 $-2.42 · · ·
Shares (Basic) 6-point trend, +208.9% 94,057,000 80,783,000 58,071,000 51,982,000 38,436,000 30,448,000 · · ·
Shares (Diluted) 6-point trend, +208.9% 94,057,000 80,783,000 58,071,000 51,982,000 38,436,000 30,448,000 · · ·
EBITDA 8-point trend, -1686.4% $-513M $-339M $-223M $-168M $-108M $-75M $-54M $-29M ·
बैलेंस शीट 24
CRNX के लिए वार्षिक बैलेंस शीट डेटा
मेट्रिक रुझान 202520242023202220212020201920182017
Cash & Equivalents 9-point trend, +615.4% $102M $265M $55M $33M $201M $93M $40M $45M $14M
Short-term Investments 8-point trend, +679.1% $926M $1.09B $504M $302M $133M $78M $78M $119M ·
Receivables 2-point trend, +592000.00 $592.0K $0 · · · · · · ·
Inventory 2-point trend, +2022000.00 $2M $0 · · · · · · ·
Prepaid Expense 9-point trend, +1733.4% $18M $21M $16M $11M $11M $7M $5M $3M $973.0K
Other Current Assets 9-point trend, +1346.0% $3M $2M $448.0K $2M $912.0K $1M $668.0K $876.0K $239.0K
Current Assets 9-point trend, +6812.9% $1.05B $1.38B $574M $345M $345M $177M $123M $167M $15M
PP&E (Net) 9-point trend, +3474.0% $14M $12M $11M $4M $3M $3M $4M $4M $400.0K
PP&E (Gross) 9-point trend, +3060.2% $22M $20M $16M $8M $6M $6M $6M $5M $704.0K
Accum. Depreciation 9-point trend, +2515.8% $8M $8M $5M $4M $3M $3M $2M $741.0K $304.0K
Other Non-current Assets 7-point trend, +8472.7% · $3M $2M $37.0K $0 $40.0K $82.0K · $33.0K
Total Assets 9-point trend, +7120.5% $1.13B $1.43B $635M $352M $351M $183M $130M $171M $16M
Accounts Payable 9-point trend, +5510.7% $23M $6M $7M $7M $3M $6M $5M $5M $403.0K
Accrued Liabilities 2-point trend, +2240.8% · · · · · · · $4M $179.0K
Current Liabilities 9-point trend, +9384.1% $85M $60M $44M $28M $16M $10M $8M $8M $897.0K
Capital Leases 7-point trend, +767.2% $42M $45M $48M $2M $3M $4M $5M · ·
Other Non-current Liabilities 3-point trend, +3240000.00 $3M $829.0K $0 · · · · · ·
Total Liabilities 9-point trend, +14484.1% $134M $110M $96M $36M $19M $15M $13M $11M $920.0K
Common Stock 4-point trend, +25200.0% · · $253.0K $0 · · · $24.0K $1.0K
Retained Earnings 9-point trend, -8614.6% $-1.42B $-952M $-654M $-439M $-275M $-168M $-94M $-43M $-16M
AOCI 8-point trend, +2957.4% $2M $963.0K $977.0K $-4M $-382.0K $25.0K $148.0K $61.0K ·
Stockholders' Equity 9-point trend, +6704.2% $992M $1.32B $539M $316M $332M $169M $117M $160M $-15M
Liabilities + Equity 9-point trend, +7120.5% $1.13B $1.43B $635M $352M $351M $183M $130M $171M $16M
Shares Outstanding 9-point trend, +6067.8% 95,575,000 92,926,000 68,175,000 53,877,000 47,597,000 33,001,000 24,263,000 24,061 1,549,575
नकदी प्रवाह 13
CRNX के लिए वार्षिक नकदी प्रवाह डेटा
मेट्रिक रुझान 202520242023202220212020201920182017
D&A 9-point trend, +2946.9% $4M $3M $1M $983.0K $922.0K $948.0K $887.0K $471.0K $128.0K
Stock-based Comp 9-point trend, +33488.2% $91M $69M $41M $28M $17M $10M $6M $2M $271.0K
Deferred Tax Flat — no change across 3 periods $0 $0 $0 · · · · · ·
Other Non-cash $-8M · · · · · · · ·
Operating Cash Flow 9-point trend, -3886.9% $-378M $-230M $-169M $-115M $-89M $-62M $-46M $-19M $-9M
CapEx 9-point trend, +1795.4% $6M $4M $5M $2M $436.0K $186.0K $492.0K $1M $304.0K
Investing Cash Flow 9-point trend, +57306.6% $174M $-575M $-200M $-174M $-56M $217.0K $42M $-119M $-304.0K
Stock Issued 7-point trend, -100.0% $0 $985M $370M $117M $250M $114M · $106M ·
Net Stock Activity 6-point trend, -100.0% $0 $970M $369M $117M $250M $114M · · ·
Financing Cash Flow 9-point trend, +243.5% $41M $1.01B $391M $122M $253M $115M $67.0K $170M $12M
Net Change in Cash 8-point trend, +10176.9% · $210M $22M $-167M $108M $53M $-5M $31M $2M
Taxes Paid 3-point trend, +89000.00 $89.0K $0 $0 · · · · · ·
Free Cash Flow 8-point trend, -1770.0% $-384M $-230M $-171M $-117M $-89M $-62M $-47M $-21M ·
लाभप्रदता 7
CRNX के लिए वार्षिक लाभप्रदता डेटा
मेट्रिक रुझान 202520242023202220212020201920182017
Operating Margin 8-point trend, -467.9% -6714.8% -32613.5% -5547.2% -3544.1% -9990.9% -105567.6% -4512.3% -1182.5% ·
Net Margin 8-point trend, -441.4% -6046.2% -28720.7% -5345.9% -3460.4% -9985.2% -103960.6% -4226.5% -1116.8% ·
Pretax Margin 8-point trend, -441.2% -6043.9% -28720.7% -5345.9% -3460.4% -9985.2% -103960.6% -4226.5% -1116.8% ·
EBITDA Margin 8-point trend, -463.6% -6664.1% -32613.5% -5547.2% -3544.1% -9990.9% -105567.6% -4512.3% -1182.5% ·
ROA 8-point trend, -25.3% -36.3% -28.8% -43.5% -46.6% -40.3% -47.0% -33.4% -29.0% ·
ROE 8-point trend, -159.9% -43.0% -27.7% -39.5% -49.1% -41.0% -41.4% -40.9% -16.6% ·
ROIC 8-point trend, -190.8% -52.1% -25.6% -41.3% -53.1% -32.5% -44.4% -46.0% -17.9% ·
तरलता और शोधन क्षमता 2
CRNX के लिए वार्षिक तरलता और शोधन क्षमता डेटा
मेट्रिक रुझान 202520242023202220212020201920182017
Current Ratio 8-point trend, -41.4% 12.3 23.0 13.1 12.5 21.6 16.9 14.8 21.0 ·
Quick Ratio 8-point trend, -41.5% 12.1 22.7 12.7 12.1 20.9 16.3 14.2 20.7 ·
दक्षता 3
CRNX के लिए वार्षिक दक्षता डेटा
मेट्रिक रुझान 202520242023202220212020201920182017
Asset Turnover 8-point trend, -76.9% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ·
Inventory Turnover 1.1 · · · · · · · ·
Receivables Turnover 26.0 · · · · · · · ·
प्रति शेयर 5
CRNX के लिए वार्षिक प्रति शेयर डेटा
मेट्रिक रुझान 202520242023202220212020201920182017
Book Value / Share 8-point trend, +55.9% $10.38 $14.26 $7.91 $5.87 $6.97 $5.12 $4827.89 $6.66 ·
Revenue / Share 4-point trend, -10.2% $0.08 $0.01 $0.07 $0.09 · · · · ·
Cash Flow / Share 4-point trend, -81.3% $-4.02 $-2.80 $-2.86 $-2.22 · · · · ·
Cash / Share 8-point trend, -43.2% $1.06 $2.85 $0.81 $0.61 $4.22 $2.82 $1662.04 $1.87 ·
EPS (TTM) 6-point trend, -104.5% $-4.95 $-3.69 $-3.69 $-3.15 $-2.80 $-2.42 · · ·
विकास दरें 3
CRNX के लिए वार्षिक विकास दरें डेटा
मेट्रिक रुझान 202520242023202220212020201920182017
Revenue YoY 5-point trend, -54.8% 640.7% -74.1% -15.3% 339.4% 1418.3% · · · ·
Revenue CAGR 3Y 3-point trend, -93.8% 17.6% -1.2% 283.8% · · · · · ·
Revenue CAGR 5Y 155.3% · · · · · · · ·
मूल्यांकन (TTM) 10
CRNX के लिए वार्षिक मूल्यांकन (TTM) डेटा
मेट्रिक रुझान 202520242023202220212020201920182017
Revenue TTM 8-point trend, +217.0% $8M $1M $4M $5M $1M $71.0K $1M $2M ·
Net Income TTM 8-point trend, -1616.1% $-465M $-298M $-215M $-164M $-108M $-74M $-50M $-27M ·
Market Cap 8-point trend, +516.6% $4.45B $4.75B $2.43B $986M $1.35B $466M $608.8K $722M ·
P/E 6-point trend, -61.3% -9.4 -13.9 -9.6 -5.8 -10.1 -5.8 · · ·
P/S 8-point trend, +94.5% 578.1 4573.0 604.5 208.1 1254.4 6558.4 0.5 297.2 ·
P/B 8-point trend, -0.4% 4.5 3.6 4.5 3.1 4.1 2.8 0.0 4.5 ·
P / Tangible Book 6-point trend, +62.7% 4.5 3.6 4.5 3.1 4.1 2.8 · · ·
P / Cash Flow 8-point trend, +68.3% -11.8 -21.0 -14.6 -8.6 -15.3 -7.5 -0.0 -37.1 ·
P / FCF 8-point trend, +67.0% -11.6 -20.7 -14.2 -8.4 -15.2 -7.5 -0.0 -35.2 ·
Earnings Yield 6-point trend, +38.0% -10.6% -7.2% -10.4% -17.2% -9.9% -17.2% · · ·

वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष

आय विवरण
2025-12-312024-12-312023-12-312022-12-312021-12-31
राजस्व $8M$1M$4M$5M$1M
परिचालन मार्जिन % -6714.8%-32613.5%-5547.2%-3544.1%-9990.9%
शुद्ध आय $-465M$-298M$-215M$-164M$-108M
तनुकरणित EPS $-4.95$-3.69$-3.69$-3.15$-2.80
बैलेंस शीट
2025-12-312024-12-312023-12-312022-12-312021-12-31
वर्तमान अनुपात 12.323.013.112.521.6
त्वरित अनुपात 12.122.712.712.120.9
नकदी प्रवाह
2025-12-312024-12-312023-12-312022-12-312021-12-31
फ्री कैश फ्लो $-384M$-230M$-171M$-117M$-89M

ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां

मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ

📊

उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।

आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।

संस्थागत मालिक (13F) 287 फाइलर्स · $3.2B कुल · तिथि अनुसार 30 जून 2026

संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।

संस्थागत गतिविधि — Q2 2026 बनाम पिछली तिमाही
नई स्थितियाँ बाहर निकली पोजीशन बढ़ाया घटा हुआ शुद्ध शेयर परिवर्तन
63 (+11 पिछली तिमाही की तुलना में) 30 (-13 पिछली तिमाही की तुलना में) 95 (-17 पिछली तिमाही की तुलना में) 63 (+3 पिछली तिमाही की तुलना में) +11.4M

Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।

संस्था मूल्य शेयर % ट्रैक किए गए 13F का प्रकार
FMR LLC $486250673 12994406 15.13% शेयर
FARALLON CAPITAL MANAGEMENT, L.L.C. $336372047 8989098 10.46% शेयर
Driehaus Capital Management LLC $241866078 6463551 7.52% शेयर
WELLINGTON MANAGEMENT GROUP LLP $237002526 6333579 7.37% शेयर
VANGUARD PORTFOLIO MANAGEMENT LLC $180836416 4832614 5.63% शेयर
VANGUARD CAPITAL MANAGEMENT LLC $177567704 4745262 5.52% शेयर
STATE STREET CORP $100635477 2689350 3.13% शेयर
Bellevue Group AG $98040400 2620000 3.05% शेयर
BAKER BROS. ADVISORS LP $87991820 2351465 2.74% शेयर
GEODE CAPITAL MANAGEMENT, LLC $87542675 2338905 2.72% शेयर
Polar Capital Holdings Plc $85108460 2274411 2.65% शेयर
Pictet Asset Management Holding SA $77572984 2075375 2.41% शेयर
Siren, L.L.C. $53165887 1420788 1.65% शेयर
First Light Asset Management, LLC $50923606 1360866 1.58% शेयर
NOVO HOLDINGS A/S $49394400 1320000 1.54% शेयर
AMERICAN CENTURY COMPANIES INC $47245129 1262562 1.47% शेयर
ADAR1 Capital Management, LLC $45730234 1222080 1.42% शेयर
DIMENSIONAL FUND ADVISORS LP $44555208 1190679 1.39% शेयर
MONTANOVA CAPITAL, LLC $44390560 1186279 1.38% शेयर
ORBIMED ADVISORS LLC $37382580 999000 1.16% शेयर
Hood River Capital Management LLC $36259830 968996 1.13% शेयर
GOLDMAN SACHS GROUP INC $34657132 926166 1.08% शेयर
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $32841401 877643 1.02% शेयर
Aberdeen Group plc $30699181 820395 0.95% शेयर
Candriam S.C.A. $30618690 819032 0.95% शेयर
VANGUARD FIDUCIARY TRUST CO $28230995 754436 0.88% शेयर
Fisher Asset Management, LLC $27748912 741553 0.86% शेयर
SCHRODER INVESTMENT MANAGEMENT GROUP $17709036 479400 0.55% शेयर
AMERIPRISE FINANCIAL INC $17451149 466356 0.54% शेयर
Impax Asset Management Group plc $16277700 435000 0.51% शेयर
Prosight Management, LP $14020002 374666 0.44% शेयर
Universal- Beteiligungs- und Servicegesellschaft mbH $13991714 373910 0.44% शेयर
KENNEDY CAPITAL MANAGEMENT LLC $13685018 365714 0.43% शेयर
BRAUN STACEY ASSOCIATES INC $13027511 348143 0.41% शेयर
Fiera Capital Corp $12395263 331247 0.39% शेयर
BANK OF AMERICA CORP /DE/ $11271877 301226 0.35% शेयर
Defilade Capital Management, L.P. $8959845 239440 0.28% शेयर
SEB Asset Management AB $8003786 213891 0.25% शेयर
Foresite Capital Management VI LLC $7933414 212010 0.25% शेयर
RICE HALL JAMES & ASSOCIATES, LLC $7346220 196318 0.23% शेयर
TD Asset Management Inc $7152534 191142 0.22% शेयर
Swiss National Bank $6877796 183800 0.21% शेयर
SEGALL BRYANT & HAMILL, LLC $6855307 183199 0.21% शेयर
BlackRock, Inc. $6781290 181221 0.21% शेयर
JENNISON ASSOCIATES LLC $6056839 161861 0.19% शेयर
New Leaf Venture Partners, L.L.C. $5872650 141000 0.18% शेयर
SILVERCREST ASSET MANAGEMENT GROUP LLC $5865136 156738 0.18% शेयर
Foresite Capital Management IV, LLC $5613000 150000 0.17% शेयर
Bank of New York Mellon Corp $5581754 149165 0.17% शेयर
NEW YORK STATE COMMON RETIREMENT FUND $5508898 147218 0.17% शेयर
ENVESTNET ASSET MANAGEMENT INC $5471384 146216 0.17% शेयर
Moody Aldrich Partners LLC $5466201 146077 0.17% शेयर
Ishara Investments LP $5369770 143500 0.17% शेयर
CITADEL ADVISORS LLC $5176271 138329 0.16% शेयर
RHUMBLINE ADVISERS $4861141 129908 0.15% शेयर
ALLIANCEBERNSTEIN L.P. $4782618 131680 0.15% शेयर
GordonMD Global Investments LP $4751779 126985 0.15% शेयर
MANUFACTURERS LIFE INSURANCE COMPANY, THE $4712974 125948 0.15% शेयर
JANUS HENDERSON GROUP PLC $4700428 129392 0.15% शेयर
Cormorant Asset Management, LP $4677500 125000 0.15% शेयर
SECTOR GAMMA AS $4289380 114628 0.13% शेयर
XTX Topco Ltd $4164547 111292 0.13% शेयर
ALPS ADVISORS INC $3981825 106409 0.12% शेयर
FEDERATED HERMES, INC. $3957390 105756 0.12% शेयर
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $3834048 105563 0.12% शेयर
Nuveen Asset Management, LLC $3760151 73541 0.12% शेयर
Burkehill Global Management, LP $3742000 100000 0.12% शेयर
Nuveen, LLC $3619262 96720 0.11% शेयर
VICTORY CAPITAL MANAGEMENT INC $3484251 93112 0.11% शेयर
MORGAN STANLEY $3320829 88744 0.10% शेयर
TWO SIGMA INVESTMENTS, LP $3266729 87299 0.10% शेयर
VANGUARD ASSET MANAGEMENT, Ltd $3254754 86979 0.10% शेयर
AWM Investment Company, Inc. $3180700 85000 0.10% शेयर
Odyssean, LLC $3160344 84456 0.10% शेयर
Affinity Asset Advisors, LLC $2806500 75000 0.09% शेयर
ALGERT GLOBAL LLC $2714147 72532 0.08% शेयर
ExodusPoint Capital Management, LP $2652404 70882 0.08% शेयर
Ensign Peak Advisors, Inc $2507290 67004 0.08% शेयर
BARCLAYS PLC $2466127 65904 0.08% शेयर
FIRST TRUST ADVISORS LP $2370631 63352 0.07% शेयर
Man Group plc $2284229 61043 0.07% शेयर
MetLife Investment Management, LLC $2258709 60361 0.07% शेयर
CITIGROUP INC $2255229 60268 0.07% शेयर
Longaeva Partners L.P. $2184879 58388 0.07% शेयर
Swedbank AB $2155392 57600 0.07% शेयर
STATE OF WISCONSIN INVESTMENT BOARD $2068016 55265 0.06% शेयर
Jump Financial, LLC $1923388 51400 0.06% शेयर
Lighthouse Investment Partners, LLC $1871000 50000 0.06% शेयर
Vestmark Advisory Solutions, Inc. $1823252 48724 0.06% शेयर
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. $1787254 47762 0.06% शेयर
VANGUARD GROUP INC $1774626 38123 0.06% शेयर
Point72 Asset Management, L.P. $1735577 46381 0.05% शेयर
BNP PARIBAS FINANCIAL MARKETS $1696398 45334 0.05% शेयर
RAYMOND JAMES FINANCIAL INC $1606254 42925 0.05% शेयर
SUSQUEHANNA INTERNATIONAL GROUP, LLP $1549188 41400 0.05% कॉल ऑप्शन
Invesco Ltd. $1545446 41300 0.05% शेयर
Vanguard Global Advisers, LLC $1485986 39711 0.05% शेयर
HighMark Wealth Management LLC $1444224 38595 0.04% शेयर
OAK RIDGE INVESTMENTS LLC $1405046 37548 0.04% शेयर
Orion Porfolio Solutions, LLC $1404234 37526 0.04% शेयर

कंपनी के अंदरूनी सूत्र 20 इनसाइडर्स · 9 अधिकारी · 10 निदेशक

अंदरूनी भूमिका अंतिम गतिविधि शेयरों का स्वामित्व खरीद 12m बिक्री 12m नेट 12m
Tobin Schilke Chief Financial Officer 10 मार्च 2025 A 52000 0 0 $0
Marc Wilson CFO 26 सितमबर 2024 M 111092 0 0 $0
Jeff E. Knight Chief Operating Officer 19 मार्च 2025 S 87491 0 0 $0
Stephen F. Betz Chief Scientific Officer 12 जून 2025 M 99713 0 0 $0
Dana Pizzuti Chief Med and Dev Officer 19 मार्च 2025 S 72233 0 0 $0
Isabel Kalofonos Chief Commercial Officer 10 जनवरी 2025 A — 0 0 $0
James Hassard Chief Commercial Officer 5 जुलाई 2024 M 29259 0 0 $0
Alan Seth Krasner Chief Medical Officer 17 अक्टूबर 2023 M 43210 0 0 $0
Ajay Madan Chief Development Officer 28 फ़रवरी 2022 A 176995 0 0 $0
Coelho Rogerio Vivaldi निदेशक 2 जुलाई 2026 S 19225 0 1 $-120000
Caren Deardorf निदेशक 18 जून 2026 A 22225 0 0 $0
Weston Nichols निदेशक 18 जून 2026 A 22225 0 0 $0
Stephanie Okey निदेशक 18 जून 2026 A 12325 0 2 $-246143
Matthew K Fust निदेशक 18 जून 2026 A 28761 0 0 $0
Camille L Bedrosian निदेशक 18 जून 2026 A 22225 0 0 $0
Wendell Wierenga निदेशक 18 जून 2026 A 122071 0 0 $0
Wendall Wierenga निदेशक 11 जून 2025 A 116146 0 0 $0
Stephen W Kaldor निदेशक 19 जून 2020 A — 0 0 $0
Jack Nielsen निदेशक 21 जून 2019 A — 0 0 $0
Richard Scott Struthers — 7 अगस्त 2026 M 424706 0 0 $0

SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S

कार्यकर्ता और 5%+ मालिक 1 होल्डिंग

जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।

फाइलर दाखिल किया दांव स्थिति उद्देश्य फाइलिंग
Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. ×6 फाइलिंग 1 मार्च 2024 — प्रारंभिक फाइलिंग — SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ईटीएफ स्वामित्व 55 ETFs द्वारा धारित

वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।

फंड भार इकाइयाँ तिथि अनुसार स्रोत
SBIO · ALPS ETF Trust 2.37% 107892 NS 31 मई 2026 N-PORT
FMED · Fidelity Covington Trust 1.65% 19000 NS 31 मई 2026 N-PORT
PILL · Direxion Shares ETF Trust 1.40% 4666 NS 30 अप्रैल 2026 N-PORT
BBP · ETFis Series Trust I 1.23% 18743 NS 30 अप्रैल 2026 N-PORT
MMSC · First Trust Exchange-Traded Fund VI… 0.75% 11043 NS 31 मई 2026 N-PORT
NUSC · Nushares ETF Trust 0.28% 93045 NS 30 अप्रैल 2026 N-PORT
BBSC · J.P. Morgan Exchange-Traded Fund Tr… 0.20% 38553 NS 30 अप्रैल 2026 N-PORT
BIB · ProShares Trust 0.19% 3872 NS 31 मई 2026 N-PORT
BKSE · BNY Mellon ETF Trust 0.15% 3142 NS 30 अप्रैल 2026 N-PORT
FNY · First Trust Exchange-Traded AlphaDE… 0.14% 18879 NS 30 अप्रैल 2026 N-PORT
RSSL · Global X Funds 0.12% 42391 NS 30 अप्रैल 2026 N-PORT
FFSM · FIDELITY COVINGTON TRUST 0.10% 31759 NS 30 अप्रैल 2026 N-PORT
ITWO · ProShares Trust 0.09% 4601 NS 31 मई 2026 N-PORT
SCHA · SCHWAB STRATEGIC TRUST 0.08% 492431 NS 31 मई 2026 N-PORT
FNX · First Trust Exchange-Traded AlphaDE… 0.07% 24991 NS 30 अप्रैल 2026 N-PORT
FHLC · FIDELITY COVINGTON TRUST 0.06% 41183 NS 30 अप्रैल 2026 N-PORT
DFAS · Dimensional ETF Trust 0.05% 196549 NS 30 अप्रैल 2026 N-PORT
UWM · ProShares Trust 0.05% 3599 NS 31 मई 2026 N-PORT
FAD · First Trust Exchange-Traded AlphaDE… 0.04% 5196 NS 30 अप्रैल 2026 N-PORT
AVIE · AMERICAN CENTURY ETF TRUST 0.04% 112 NS 31 मई 2026 N-PORT
URTY · ProShares Trust 0.04% 3643 NS 31 मई 2026 N-PORT
GSSC · Goldman Sachs ETF Trust 0.02% 5689 NS 31 मई 2026 N-PORT
MSSM · MORGAN STANLEY PATHWAY FUNDS 0.02% 3773 NS 31 मई 2026 N-PORT
HDG · ProShares Trust 0.02% 91 NS 31 मई 2026 N-PORT
DFAC · Dimensional ETF Trust 0.01% 125853 NS 30 अप्रैल 2026 N-PORT
ONEQ · Fidelity Commonwealth Trust 0.01% 28694 NS 31 मई 2026 N-PORT
DCOR · Dimensional ETF Trust 0.01% 5863 NS 30 अप्रैल 2026 N-PORT
TILT · FlexShares Trust 0.01% 3388 NS 30 अप्रैल 2026 N-PORT
DFUS · Dimensional ETF Trust 0.01% 31413 NS 30 अप्रैल 2026 N-PORT
DFAU · Dimensional ETF Trust 0.01% 15024 NS 30 अप्रैल 2026 N-PORT
SCHB · SCHWAB STRATEGIC TRUST 0.01% 60503 NS 31 मई 2026 N-PORT
DXUV · Dimensional ETF Trust 0.00% 468 NS 30 अप्रैल 2026 N-PORT
VXF · VANGUARD INDEX FUNDS — — 15 जुलाई 2026 दैनिक
VB · VANGUARD INDEX FUNDS — — 15 जुलाई 2026 दैनिक
VBK · VANGUARD INDEX FUNDS — — 15 जुलाई 2026 दैनिक
VTI · VANGUARD INDEX FUNDS — — 15 जुलाई 2026 दैनिक
VT · VANGUARD INTERNATIONAL EQUITY INDEX… — — 15 जुलाई 2026 दैनिक
VTWO · VANGUARD SCOTTSDALE FUNDS — — 15 जुलाई 2026 दैनिक
VTWG · VANGUARD SCOTTSDALE FUNDS — — 15 जुलाई 2026 दैनिक
VTHR · VANGUARD SCOTTSDALE FUNDS — — 15 जुलाई 2026 दैनिक
ITOT · iShares Trust — — 5 अगस्त 2026 दैनिक
IWV · iShares Trust — — 18 अगस्त 2026 दैनिक
IWO · iShares Trust — — 18 अगस्त 2026 दैनिक
IWM · iShares Trust — — 18 अगस्त 2026 दैनिक
IBB · iShares Trust — — 18 अगस्त 2026 दैनिक
IHE · iShares Trust — — 18 अगस्त 2026 दैनिक
PRFZ · Invesco Exchange-Traded Fund Trust — — 4 अगस्त 2026 दैनिक
OMFS · Invesco Exchange-Traded Self-Indexe… — — 13 जुलाई 2026 दैनिक
VHT · VANGUARD WORLD FUND — — 20 जुलाई 2026 दैनिक
ESGV · VANGUARD WORLD FUND — — 30 जुलाई 2026 दैनिक